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Abstract
Accessory pathways are present in 1 in 300 young individuals. They are often asymp-
tomatic and potentially lethal arrhythmias may be the first presentation. During long-
term follow-up, up to 20% of asymptomatic individuals with pre-excitation go on to
develop an arrhythmia and the absence of traditional clinical and electrophysiological
high-risk markers does not guarantee the “safe” nature of an accessory pathway. The
widespread availability of permanent cure for the condition at low risk by catheter
ablation, creates an incentive to screen for accessory pathways with a 12-lead ECG,
particularly in individuals who are perceived to be at increased risk, such as athletes
and high-risk professions. We review the existing literature on the assessment and
management of accessory pathways (Wolff-Parkinson-White [WPW] syndrome) and
discuss its implications for the young athletic population.
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1 | INTRODUCTION
Accessory pathways (Wolff-Parkinson-White Syndrome [WPW]) are
often asymptomatic and potentially lethal arrhythmias may be the first
presentation. Due to the requirement for cardiac screening with a
12-lead ECG in most athletic disciplines and associated sporting orga-
nizations, a pre-excitation pattern may be identified in otherwise
healthy individuals. This review aims to address in a systematic way
the assessment and management of WPW, with particular emphasis
on the athletic population.
2 | METHODOLOGY
For the purpose of this review, a search for available literature between
1930 and 2020 was conducted, using PUBMED, using the key words:
Wolff-Parkinson-White, pre-excitation, athletes, accessory pathway,
sudden cardiac death, life-threatening events, screening, and ablation. A
summary of the key studies included in the review is outlined in Table 1.
3 | HISTORY AND TERMINOLOGY
Drs Louis Wolff, John Parkinson, and Paul Dudley White described
what they believed was an association between left bundle branch
block and supraventricular tachycardia.1,2 It was not a blocked bundle
branch but broadening of the QRS due to excitation reaching the ven-
tricle before conduction could reach it through the His-Purkinje sys-
tem. This pre-normal excitation, or pre-excitation of the ventricular
myocardium was via an accessory pathway, an abnormal electrophysi-
ological connection between the atria and the ventricles.
An accessory pathway provides an additional route for conduc-
tion from atrium to ventricle and vice versa, bypassing the His-
Purkinje system and AV node; it is therefore often also called a
“bypass tract.” The presence of an accessory pathway leaves the
patient vulnerable to two forms of arrhythmia: re-entrant arrhythmias
due to the second route of conduction and accelerated conduction of
atrial arrhythmias because the pathway bypasses the protection of
the AV node. Pre-excited atrial arrhythmias, particularly atrial fibrilla-
tion (AF) can be lethal. The atrial fibrillation cycle length (CL) is
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variable and short, typically between 150 and 250 ms. But the atrial
rate of up to 300 beats per minute can, in some cases, be transmitted
directly to the ventricles producing ventricular fibrillation and sudden
cardiac death (SCD).3-6
The prevalence of WPW in the general population is estimated at
0.1 to 4.5 per 1000 individuals.7-9 It is usually an isolated abnormality
in an otherwise normal heart in a healthy person. A small minority
occur as part of structural congenital or genetic cardiac conditions,
notably Ebstein's anomaly or glycogen storage disorders.10-13 The
management discussed in this article may not necessarily apply to
those with these underlying conditions. Patients with these underlying
conditions may present in various ways including, familial cascade
TABLE 1 Key studies reviewed in this article
Key studies
reviewed Year of publication and type of study Number and type of patients studied Summary of findings
Garg et al.42 2017. Retrospective study of outcomes
after WPW catheter ablation in the
United States over a period of
14 years from 1998 to 2011.
2329 patients had WPW catheter
ablation in this time period according
to ICD coding.
Catheter ablation is a safe procedure
with low morbidity and mortality risk.
Cardiac tamponade occurred in 0.9%
of cases; complete heart block
occurred in 1% of cases.
Liberman
et al.45
2014. Retrospective single-centre study
of all anteroseptal AP cases who
underwent cryoablation during the
period of 2005-2012.
70 patients <21 years of age had
anteroseptal AP and received
cryotherapy ablation treatment.
Septal pathway ablation in young
patients using cryotherapy had no






912 subjects <21 years old from general
population, diagnosed with WPW
from EP study.
Life-threatening events may occur
despite the absence of high risk
features from EP study or prior




2003. Prospective randomised trial of
asymptomatic WPW patients.
Asymptomatic WPW patients. 224 were
eligible for the study with final study
participants of 37 randomised to
ablation group and 35 randomised to
control group.
1 control group patient had an aborted
VF cardiac arrest. The 5 year
Kaplan-Meier survival estimates of
incidence of arrhythmic events were
7% in ablation group versus 77% in
controls (P < .001).
Pappone
et al.48
2012. Prospective long-term follow-up
study of those who had EP study for
WPW.
8575 patients with symptomatic WPW
from AVRT had EP study. 369 patients
declined ablation treatment after EP
study and had long-term follow up.
No cases of mortality were recorded in
those who refused ablation in this
study. 1.1% of the non-ablation
cohort had a life-threatening event
during the 5 year follow-up period.
Short pathway anterograde ERP is a
robust marker of risk.
Malhotra
et al.29
2018. Retrospective study of a
nationwide structured cardiac
screening program of elite footballers.
11 168 elite level football players; 95%
male.
Based on this study, the incidence of
SCD was at 6.8 per 100 000 athletes.
26 cases of pre-excitation pattern
were found; 24 were ablated. Two
followed up clinically and no cases of
WPW related death or aborted SCD
were confirmed. All 26 resumed their
normal competitive athletic career.
Finocchiaro
et al.6
2017. Retrospective review of cardiac
pathology database of all SCD cases
received from 1994-2014.
3684 cases of SCDs found 19 cases with
a prior clinical diagnosis of WPW
before death.
Key findings of SCD deaths with prior
WPW ECG patterns include; deaths
may occur at rest and without prior
symptoms. Deaths may occur after
the 4th decade. Co-morbidities
existed which increased risk of AF.
Borregaard
et al.52
2015. Retrospective cohort single-centre
study of WPW patients who had RF
ablation.
362 WPW patients who had catheter
ablation for WPW.
Post ablation follow up reveals that
mortality risk is similar to background
population and confirms that there
are no long-term adverse effects of
ablation treatment in this cohort.
Interestingly, the incidence of AF later
on in life was higher in the
post-ablation WPW group.
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screening, cardiac imaging to investigate symptoms or incidentally in
cases where investigations were requested for other clinical reasons.
Most individuals with pre-excitation never experience an arrhyth-
mia.14 Accessory pathways often present in the teenage years or early
adult life. They rarely produce arrhythmias in-utero and only occasion-
ally in infancy or early childhood. Because of the potential for lethal
arrhythmias and the possibility to be corrected safely and perma-
nently, pre-excitation has an importance disproportionate to its rela-
tive rarity. The great majority of patients do not require long-term
follow after treatment by ablation, and can resume normal activity
including intense exercise. It is therefore important that the physician
recognize the condition and refer individuals for appropriate evalua-
tion and treatment with an appropriate level of urgency.
4 | ANATOMICAL AND
ELECTROPHYSIOLOGICAL FEATURES
Accessory pathways can be found at any point around the AV ring:
left lateral locations are most common, septal and right sided ones
slightly less so; they have even been described in the aorto-mitral
continuity. A small proportion run from the compact AV node to the
ventricle via the fascicle or directly (called nodofascicular and
nodoventricular pathways, respectively) and a few have decremental
conduction properties like the tissue of the AV node (Mahaim fibres),
but most are just strands of myocardium that traverse the AV groove
and have conduction properties similar to atrial myocardium.15-18 This
structure can exhibit varied electrophysiological properties, probably
in part due to variable branching and arboreous features.
The most important electrophysiological properties of a pathway
are its anterograde effective refractory period (RP) and its directional-
ity.19-20 Approximately half of accessory pathways conduct in one
direction only, most commonly from ventricles to atria (retrogradely).
A pathway that conducts only anterogradely can produce pre-
excitation in AF, but seldom supports a regular re-entrant arrhythmia;
a pathway that conducts only retrogradely cannot accelerate the con-
duction of an atrial arrhythmia, so presents little danger apart from
symptomatic atrio-ventricular reciprocating tachycardia (AVRT). Dan-
ger is a product of the anterograde RP of a pathway: A short RP
means that the pathway can conduct successive depolarizations at
short intervals, therefore risking ventricular activation during AF at a
rate fast enough to trigger ventricular fibrillation.
As the electrophysiological property and behavior of an AP may
vary, the terms manifest, latent and concealed have been used to
describe and clarify this. A manifest accessory pathway is one that
conducts anterogradely and often can conduct bi-directionally (both
anterograde and retrograde). A concealed AP cannot conduct
anterogradely and so there is no evidence of pre-excitation on the
ECG. The absence of anterograde conduction makes such a pathway
incapable of causing sudden death by pre-excited AF. Latent pre-
excitation refers to anterograde pathway conduction unmasked by
certain conditions of the atria and/or the AV node but not seen on
the ECG at other times because normal conduction reaches the
ventricles before conduction via the pathway. Delaying conduction
via the AV node, for example by administering adenosine, can reveal
the pathway; pre-excitation can also be unmasked by premature atrial
complexes or by the occurrence of AF.
5 | WPW AND THE ATHLETE: WHAT'S
DIFFERENT?
In classical times, Pheidippides' death after the battle of Marathon
was not questioned;21 having apparently run 84 km in a day, his sub-
sequent death seemed unremarkable. Now, sport has become more
varied, extreme and often over a prolonged duration of time in a per-
son's lifetime, with increasing numbers of people who identify them-
selves as veteran athletes emerging. The effect of decades of sporting
participation on a person's physiology and development of pathophys-
iological conditions is incompletely understood.22
Wolff-Parkinson-White accounts for 1% of SCD in the athletic
population based on a long-term registry but this is likely to be an
underestimate due to lack of ECG screening.23 Diagnosing WPW as a
cause of sudden death is difficult; autopsy examination of the heart
cannot reliably identify the existence of accessory pathways as this
would require extensive dissection of the atrioventricular groove, a
time-consuming process that is not included in a standard autopsy. As
such it is possible that a proportion of SCDs secondary to WPW
related arrhythmias may be attributed to a structural normal heart also
referred as Sudden Arrhythmic Death Syndrome (SADS), which is rec-
ognized as a common cause of SCD in contemporary studies in young
and athletic individuals.24-26
Athletic activity accentuates the risk of pre-excitation related
SCD; in one survey, two thirds of the study population suffered from
an aborted VF cardiac arrest during exercise or under emotional
stress27; in the more recent Italian registry, exercise related events
remained high at 36%.20 Even in sedentary individuals with pre-exci-
tation, exertions of daily life may precipitate an arrhythmia. Exercise-
related adrenergic activation accelerates AV nodal conduction in both
directions, increasing vulnerability to re-entrant tachycardias and the
rate of the tachycardia induced. It may therefore increase the risk of a
regular tachycardia disorganizing to AF and precipitating ventricular
fibrillation.
Participation in organized athletics presents an opportunity, as
screening is used to exclude a variety of conditions, and pre-excitation
can be detected and treated as a result. Because athletic training and
competitions are organized by schools, societies and companies, a
duty of care is created that involves organizations with the logistical
capacity to deliver screening and alongside this be sensitive to the
associated ethical and legal considerations.28
6 | SCREENING FOR ATHLETES
A study by Malhotra et al.29 looked at the outcomes of cardiac screen-
ing in elite football players and found that pre-excitation was picked
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up in 26 cases out of a total of 11 168 who underwent screening at
the age of 16.4 ± 1.2 years. None of these suffered from a life-
threatening event: 24 cases were ablated and resumed playing and
the other two had low risk features and continued to compete with
no adverse events recorded.
Screening for the conditions that predispose to SCD in athletes
often includes a resting 12-lead ECG alongside a focused history and
a clinical examination. However, the screening protocol can vary
depending on the type of organization providing it. In the case of
manifest pre-excitation, the diagnosis derives from the ECG. Good
history-taking and clinical judgement remains important not only for
risk stratification purposes, but also because symptoms may be the
only evidence of latent or concealed pre-excitation. The symptoms
that are most strongly suggestive of arrhythmias are recurrent syn-
cope, pre-syncope and sustained palpitation, particularly when associ-
ated with exercise. To make the screening process more challenging,
athletes may not report or under report symptoms for fear of inter-
ruption to their training, funding or other impact to their career.
The electrocardiographic hallmarks of pre-excitation are a PR
interval shorter than 120 ms and a slurred upstroke to the QRS com-
plex known as a delta wave for its shape. The degree to which pre-
excitation is evident depends on the relative time taken for a sinus
beat to conduct to the ventricle via the accessory pathway and via
the conduction system. Activation takes so long to reach a pathway in
a left lateral location that AV nodal conduction will often beat it, mas-
king its presence. A patient with WPW may therefore have a perfectly
normal ECG even with a rapidly conducting pathway with a short
anterograde RP (Figure 1).
The pattern of the pre-excitation on the ECG can be dynamic.30
The existence of pre-excitation on an ECG may be subtle and easily
missed. The ECG must be analyzed systematically: the PR interval
measured precisely, the onset of the QRS complex inspected for slur-
ring, the QRS axis and transition defined. Automated analysis provides
a reasonably reliable way of supporting this process, but confirmation
by an expert cardiologist is still required. Any patient showing abnor-
mality of any of these indices must be considered for possible pre-
excitation. However, a short PR interval, in isolation, is known to be a
physiological finding in a young person or athlete, representing rapid
AV nodal conduction. In electrophysiological study, there is a refer-
ence range for normal AH intervals (50-120 ms)31 in healthy subjects
and this is dependent on autonomic efferent output.
7 | POST-SCREENING INVESTIGATION
7.1 | Non-invasive tests
When the surface ECG is inconclusive, an ambulatory ECG may help
to clarify whether pre-excitation is present. Over the course of any
24-h period, conduction via the AV node varies, and periods of slower
conduction will make pre-excitation more evident. Atrial premature
beats may provide even greater accentuation of pre-excitation, partly
by their prematurity which elicits slower conduction via the AV node
due to its decremental conduction properties, partly due to the site of
origin: Ectopics arising in the left atrium reach the atrial insertion of a
left sided pathway before reaching the AV node, making the pathway
conduction more evident.
The ambulatory ECG may also help to clarify the risk associated
with an accessory pathway by revealing arrhythmias mediated by it
and by providing a measure of the AERP. Most re-entrant arrhythmias
produce symptoms, but in a few cases asymptomatic arrhythmias are
revealed. Information about the anterograde RP is difficult to extract
because the temporal resolution of Holter systems is less than that of
12-lead ECG systems and the quality is often inferior. In some cases,
particularly when atrial premature beats are present and represent a
spread of coupling intervals, useful information may be derived.
The abrupt and complete loss of pre-excitation during an exercise
treadmill test provides a good measure of the anterograde RP of a
F IGURE 1 An example of latent pre-excitation: a 12 lead ECG in sinus rhythm and another documenting preexcited AF in the same patient
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pathway and therefore of the risk it produces.32-34 In the real world,
the phenomenon can only be seen in a minority of pediatric and adult
cases and that there is a wide discrepancy in observer interpretation.
The difficulty arises from the normal tendency for conduction via the
AV node to accelerate as the sinus rate increases with exercise. This
produces a progressive encroachment of the sharp part of the QRS
upstroke produced by the His-Purkinje system on the delta wave pro-
duced by the AP, masking the existence of pre-excitation.
In some cases, the surface ECG is suggestive of pre-excitation but
not diagnostic. If the ambulatory ECG does not clarify this issue
(Figure 2), injection of adenosine can usually do so. A sufficient bolus
of adenosine injected into a large vein will cause transient block of AV
nodal conduction; if a pathway with anterograde conduction is pre-
sent, it will be unmasked by this.35 If one or more P waves are blocked
from AV conduction, then it is safe to conclude that no clinically dan-
gerous accessory pathway is present.
Intermittent pre-excitation is not considered to be a robust sign of a
low risk pathway although there is some evidence that intermittent path-
way activity is associated with a long anterograde effective refractory
period.36 Recent studies and the 2019 ESC guidelines support the fact that
intermittent pre-excitation is a weak and flawed sign of low risk: >20% of
these cases go on to have EPS confirmation of AP ERP <250 ms.37,38
7.2 | Invasive tests
The diagnostic electrophysiological study (EPS) provides a robust mea-
sure of the anterograde effective refractory period of any pathway
and is the best verified method of risk stratification.9,20,39A refractory
period of <250 ms is a reproducible indicator of a high-risk pathway. In
the electrophysiology lab, AF can easily be induced and the shortest
R-R interval in AF can be measured; the occurrence of intervals
<250 ms is also another high-risk feature. The more definitive risk
stratification of invasive EPS must be weighed against the minor risks
involved, such as 1% chance of hematoma at the access site which is
rarely more than a transient nuisance. It is also worth noting that in
practice, the diagnostic EPS is almost always used as a prelude to cura-
tive catheter ablation rather than as a stand-alone procedure.
8 | TREATMENT
8.1 | Medical therapy
Offering blanket suppression of arrhythmic potential by long-term medica-
tion is inappropriate due to the very low rate of clinical success, the long-
term risk of adverse effects including lethal arrhythmias provoked by
prolongation of the QT interval or slowing of conduction, and interference
with the athlete achieving his/her athletic potential. In general, regular anti-
arrhythmic medication should only be considered in symptomatic patients
as short-term instruments of symptom control if ablation is not immedi-
ately available,40 or to those who refuse ablation. Sometimes, there may be
specific reasons for declining ablation including the pathway being close to
the conduction system resulting in a high risk of complete AV block.
8.2 | Ablation
The cure rate of accessory pathways by ablation now approaches
100%, with more than 90% of patients obtaining permanent cure on a
F IGURE 2 Ambulatory ECG findings that rule out pre-excitation. This athlete was investigated because of a relatively short PR interval
(115 ms) with non-specific broadening of the QRS complex on a routine 12-lead ECG. A 5-day, single derivation recording was performed. This
shows lengthening of the PR interval to 200 ms during sleep without alteration of the QRS complex. There are also instances of second degree
AV block during sleep (black arrow) and atrial premature beats which are conducted at a longer PR interval without alteration in the QRS
complex. All of these features indicate that either the patient has no pathway capable of anterograde conduction or that the AERP of the
pathway is longer than the sinus cycle present at the time of the second degree AV block, which was over 1 s
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first attempt (Figure 3).36,38 Ablation is typically performed under local
anesthesia for adult patients, often under general anesthesia for chil-
dren. Venous vascular access and cannulation is almost always via the
femoral vein(s) and may be guided by ultrasound.41 The procedure
involves a baseline EPS to determine the electrophysiological properties
of the AP and define its location. This provides the basis for a risk-
benefit calculation to decide whether to proceed to ablation, and which
method to use: Radiofrequency (RF) is usually chosen for its rapidity and
reliability, but cryotherapy may be chosen. Successful ablation is
achieved within seconds of the start of RF delivery and is indicated by
disappearance of pathway conduction. It is usual to observe for a
waiting period of 20 to 30 min and to perform adenosine testing.
The safety profile of catheter ablation treatment has been docu-
mented by Garg et al.42 They reviewed WPW catheter ablation proce-
dures performed in the United States over a period of 14 years and
found that among 11 601 ablations performed, there was no case of
in-hospital mortality associated with the procedure. Cardiac tamp-
onade occurred in 0.9% of cases. Complete heart block was seen in
1% of this series of ablations performed in the period of 1998 to
2011 but is only relevant to a small and well-defined minority of path-
ways located close to the conduction system.
Septal pathways accounted for approximately 25% of a series of
1969 cases undergoing EPS.43 Septal pathways may be so close to
the conduction system that there is a risk of causing complete AV
nodal block during ablation. In children, this risk has been quoted at
10% for mid-septal pathways using RF energy but more recent litera-
ture in the same population reports a risk of <1% using
cryotherapy.44-46
Compared to RF, cryotherapy has the advantage of partial revers-
ibility: Tissue that is cooled ceases to conduct long before it sustains
permanent injury. For this reason, cryotherapy is often chosen when
the pathway lies within 5 mm of the His bundle or the compact AV
node.47 Cryotherapy also has the advantage of being painless,
whereas RF can be moderately painful in some locations. Ablation
technology has advanced greatly since the period covered by the Garg
series, but no substantial series is available to determine the effect on
safety.
An EPS study with a view to ablation is recommended in all symp-
tomatic individuals.38 A detailed long-term follow up study of
369 WPW patients who presented with symptoms but declined cath-
eter ablation, was conducted by Pappone et al.48 There were no
deaths, but four patients (1.1%) suffered from hemodynamic collapse
with pre-excited AF or VF and a further 25 (6.8%) had pre-syncope or
syncope. The study demonstrated that almost 2% of symptomatic
patients suffer life-threatening arrhythmias for each year that ablation
is delayed, confirming the routine use of ablation as first line therapy.
F IGURE 3 Treatment of WPW. At the left of the figure, the patient has obvious pre-excitation. This had been present from birth and had
caused a near-arrest due to pre-excited atrial fibrillation. Radiofrequency energy begins at the time indicated, and <3 s later the pathway becomes
blocked. The patient now has a normal heart, and it will remain so for life
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When pre-excitation is identified in a young and asymptomatic
athletic individual, the question asked is whether there is a case for
completely non-invasive management. Risk assessment of the AP
must take place before the athlete can be deemed “cleared” in
preparticipation. An EPS ± ablation is considered first line investiga-
tion in the majority of cases and a referral to cardiac electrophysiology
is therefore recommended in all, including asymptomatic individuals.
A small randomized controlled trial on asymptomatic pre-excitation
found that the group who received ablation had fewer arrhythmic
events compared to the control group (7% vs 77%; P < .001) over a
period of 5 years.49 One patient in the control group suffered from an
aborted VF cardiac arrest. A more recent analysis from the same group
demonstrated that the prognosis of the Wolff-Parkinson-White syn-
drome depends on intrinsic electrophysiological properties of AP rather
than symptoms, further supporting the need for an EPS study for risk
stratification of these individuals with ablation performed during the
same procedure in many to improve prognosis.20
A recent systematic review of the management of asymptomatic
children with pre-excitation found that management for this age group
follows similar principles to those in adults. Raposo et al.50 found that
the cut off age of 8 years or greater was adhered to as recommended
under 2012 pediatric guidance. Identification of the shortest pre-excited
R-R interval (SPERRI) <250 ms was still the best predictor for risk stratifi-
cation. In pediatric cases, the adjunctive use of isoproterenol to enhance
the sensitivity of risk stratification was common as the procedures are
generally performed under general anesthesia. The review confirmed
that in asymptomatic children, prophylactic ablation is offered if there is
a finding of a short anterograde RP or short RR intervals in AF. The pres-
ence of multiple pathways was also a factor taken into account.
Etheridge et al. reported on 96 children with WPW who had a life-
threatening event.51 The majority did not have prior symptoms. 10% of
events occurred whilst participating in sporting activities. They highlight
the limitations of all modes of risk stratification: 25% of their series of
patients who had suffered a life-threatening event had neither an induc-
ible tachycardia nor any other definable risk factor, possibly due to use
of anesthesia during EPS or due to a failure to define the anterograde RP
of the pathway because of atrial refractoriness. The authors concluded
that for both young athletic individuals and children with an accessory
pathway, life-threatening events may occur without any prior symptoms,
and without traditional markers of high risk on EPS and exercise restric-
tion alone does not keep athletes or children safe. They recommend the
adoption of a low threshold for ablation in children with pre-excitation.
8.3 | What the 2019 guidelines add
The 2019 ESC guidelines for the management of patients with supra-
ventricular tachycardia provide a good summary of the acute and
F IGURE 4 Risk stratification for asymptomatic pre-excitation. Redrawn and modified from fig. 22, section 11, 2019 ESC Guidelines
(Reference 38)
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long-term management of WPW.38 On asymptomatic pre-excitation,
it confirms that formal follow up is required as 20% of these patients
will go on to develop symptoms. Importantly, the guidelines establish
EPS as the first-line tool for risk stratification in all individuals with
pre-excitation, irrespective of symptoms, class I recommendation for
competitive athletes or high-risk occupations and IIa recommendation
for all others. With data from a Danish registry,52 it is also able to clar-
ify that right antero-septal APs may be linked to future development
of AF and heart failure and that mortality risk associated with this AP
location was higher even in the older age group of >65. This associa-
tion had not previously been recognized. A summary of risk stratifica-
tion for asymptomatic pre-excitation, adapted from the 2019
Guidelines, is outlined in Figure 4.
9 | CONCLUSIONS
Cardiac screening in the young and athletic cohort may uncover pre-
excitation. Evidence of an accessory pathway is significant even if the
individual is asymptomatic at the time. The condition is potentially
lethal if unrecognized but is amenable to a safe and permanent cure
once diagnosed.
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